NTRB Stock Analysis: Buy, Sell, or Hold?
NTRB - Nutriband Inc. Common Stock
$4.67
0.85 (22.32%)
▲
5d:
+41.41%
30d:
+59.26%
90d:
+33.71%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Sep 08, 2026
15d
Get Alerted When NTRB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: NTRB is 33.3% above its trading range ($3.50). Market expects 7.3% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: NTRB is 33.3% above its trading range ($3.50). Market expects 7.3% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$5.28
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$3.28
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 2.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NTRB is currently trading at $4.67, which is considered extended relative to its 30-day fair value range of $2.78 to $3.50. From a valuation perspective, the stock is trading at a premium (Forward PE: 3.2) compared to its historical average (2.6). At these levels, the market is pricing in 7.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, NTRB is in a downtrend. The price is approaching resistance at $4.75. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 22.3% recently.
Market Sentiment: NTRB scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $15.00 (+221.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NTRB is in a downtrend. The price is approaching resistance at $4.75. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 22.3% recently.
Market Sentiment: NTRB scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $15.00 (+221.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.78 -
$3.50
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
22.9%
All Signals
- BEARISH: Price significantly overextended (+33.3% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+22.3%)
- BULLISH: Trading 221.4% below Wall St target ($15.00)
- NEUTRAL: Trading at premium valuation - market expects 7.3% growth which is achievable
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.78 -
$3.50
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.05
Resistance Level
$4.75
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
3.22
Wall Street Target
$15.00
(+221.4%)
Revenue Growth (YoY)
-35.1%
Valuation Premium vs History
+7.3% premium
PE vs Historical
3.2 vs 2.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+7.3%
(market-implied from PE analysis)
1-Year Target
$5.01
(+7%)
2-Year Target
$5.37
(+15%)
3-Year Target
$5.76
(+24%)
3-Yr Target (if PE normalizes)
(PE: 3→3)
PE COMPRESSION
$4.66
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: August 22, 2026 7:08 PM ET
Data refreshes hourly during market hours. Next update: 8:08 PM
Data refreshes hourly during market hours. Next update: 8:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NTRB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
